Any thoughts on the difference between CX601 and Takeda's Alofisel? is this the same disease?
Wondering whether we expect royalties from Takeda at some point? From what I can gather, Takeda acquired TiGenix in 2018 with the MSB licence to TiGenix that you posted dated at end of 2017.
Something I came across recently has been that Alofisel is priced at 5.62 million yen (https://pj.jiho.jp/article/245593) - this compares to Temcell pricing of 868,680 yen/bag of cells in 2015 at an average of 16-24 bags per adult patient (https://www.globenewswire.com/news-release/2015/11/27/790909/0/en/Mesoblast-s-Japan-Licensee-Receives-Pricing-for-TEMCELL-HS-Inj-for-Treatment-of-Acute-Graft-Versus-Host-Disease.html#:~:text=Reimbursement%20for%20TEMCELL%20has%20been,bags%20of%2072%20million%20cells.)
Notably, most Japanese patients are paediatric (https://ssl4.eir-parts.net/doc/4552/ir_material_for_fiscal_ym3/125140/00.pdf) and therefore presumably use less bags - also note that in the linked document there is a statement about COVID impacts on bone marrow banks - potentially impacts Temcell revenue in near future
MSB 2023 - awaiting for Ryoncil approval, page-581
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.070(6.57%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | 99.5¢ | $3.980M | 3.944M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 56239 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 103125 | 2 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |